Advertisement

International Journal of Hematology

, Volume 110, Issue 2, pp 131–146 | Cite as

JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)

  • Ken OhmachiEmail author
Guide Line

Overview

Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) as defined in the 2017 WHO classification [1] accounts for over 30% of all non-Hodgkin lymphomas (NHL) in Japan [2], making it the most prevalent form of NHL. DLBCL can occur as primary disease or through histologic transformation from other low-grade B-cell lymphoma, and is an inhomogeneous group of various entities. It can be classified into subtypes of germinal center B-cell lymphoma and active B-cell/non-germinal center B-cell lymphoma based on cell origin determined by immunohistochemical staining for markers such as CD10, BCL6, and IRF4/MUM1 [3]. However, treatment stratification by subtype is currently only performed in clinical trials.

This chapter will cover DLBCL, NOS as well as certain DLBCL subtypes (T-cell/histiocyte-rich large B-cell lymphoma; primary DLBCL of the central nervous system; primary cutaneous DLBCL, leg type; and EBV positive DLBCL, NOS) and related entities (primary mediastinal...

Notes

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Department of Hematology/OncologyTokai University School of MedicineIsehara-shiJapan

Personalised recommendations